METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R...
METEOR: Background <ul><li>Previous results from A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasoun...
METEOR: Background <ul><li>The goal of the present trial was to evaluate the effect of rosuvastatin compared with placebo ...
METEOR Trial: Study Design <ul><ul><li>Primary Endpoint: Annualized rate of change in maximum CIMT </li></ul></ul><ul><ul>...
METEOR Trial: Primary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically si...
METEOR Trial: Secondary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically ...
METEOR Trial: Secondary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically ...
METEOR Trial: Secondary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically ...
METEOR Trial: Limitations <ul><li>The impact of aggressive lipid lowering on clinical events was not evaluated in this tri...
METEOR Trial: Summary <ul><li>Among asymptomatic patients at low risk for cardiovascular disease, treatment with rosuvasta...
of 10

Presented at ACC 2007

Published on: Mar 4, 2016
Source: www.slideshare.net


Transcripts - Presented at ACC 2007

  • 1. METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R. Crouse III Measuring Effects of Intima-Media Thickness: An Evaluation of Rosuvastatin
  • 2. METEOR: Background <ul><li>Previous results from A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound [ASTEROID] illustrated that intensive lipid lowering with rosuvastatin over 24 months resulted in a significant regression of coronary atherosclerosis as measured by intravascular ultrasound. </li></ul><ul><li>However, ASTEROID was not a placebo controlled study and did not have clinical end points. </li></ul>ACC 2007
  • 3. METEOR: Background <ul><li>The goal of the present trial was to evaluate the effect of rosuvastatin compared with placebo on carotid intima-media thickness (CIMT) over 2 years among asymptomatic patients at low risk for cardiovascular disease. </li></ul>ACC 2007
  • 4. METEOR Trial: Study Design <ul><ul><li>Primary Endpoint: Annualized rate of change in maximum CIMT </li></ul></ul><ul><ul><li>Secondary Endpoint: Annualized rate of change in maximum CIMT derived from the near and far walls of the right and left common carotid artery; the right and left carotid bulb; the right and left internal carotid artery; and annualized rate of change in mean CIMT for the near and far walls of the right and left common carotid artery. </li></ul></ul>Rosuvastatin ( 40mg) n=702 Placebo n=282 984 asymptomatic patients with moderately elevated cholesterol and low risk of CVD according to the National Cholesterol Education Program Adult Treatment Panel III guidelines criteria (0-1 risk factor and LDL 120-190mg/dL or > 2 risk factors and LDL 120 to <160mg/dL with a 10-year coronary heart disease risk < 10%); HDL-C < 60mg/dL; triglycerides <500mg/dL; evidence of thickening of the walls of the extracranial carotid arteries as measured by B-mode ultrasound (max CIMT between 1.2 and <3.5mm) 5:2 Randomized. Double-blinded. Placebo-controlled. Mean age = 57 years. 40% Female. R 6, 12, 18 and 24 mos. follow-up ACC 2007
  • 5. METEOR Trial: Primary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically significant reduction in the rate of progression of CIMT thickening in overall carotid segments, while the placebo group displayed progression (p<0.001). </li></ul>Change in CIMT for 12 Carotid Artery sites (mm/year) n = 702 n = 282 p < 0.001 ACC 2007 Change in maximum CIMT with rosuvastatin vs. placebo Rosuvastatin Placebo
  • 6. METEOR Trial: Secondary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically significant reduction in the rate of progression of CIMT thickening in common carotid sites, while the placebo group displayed progression (p<0.001). </li></ul>Change in CIMT for common carotid sites (mm/year) n = 702 n = 282 p < 0.001 ACC 2007 Change in maximum CIMT with rosuvastatin vs. placebo Rosuvastatin Placebo
  • 7. METEOR Trial: Secondary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically significant reduction in the rate of progression of CIMT thickening in carotid bulb sites, while the placebo group displayed progression (p<0.001). </li></ul>Change in CIMT for carotid bulb sites (mm/year) n = 702 n = 282 p < 0.001 ACC 2007 Change in maximum CIMT with rosuvastatin vs. placebo Rosuvastatin Placebo
  • 8. METEOR Trial: Secondary Endpoint <ul><li>After two years, treatment with rosuvastatin was associated with a statistically significant lower progression in CIMT thickening in internal carotid sites as compared with the placebo group (p=0.02) </li></ul>Change in CIMT for internal carotid artery sites (mm/year) n = 702 n = 282 p = 0.02 ACC 2007 Change in maximum CIMT with rosuvastatin vs. placebo Rosuvastatin Placebo
  • 9. METEOR Trial: Limitations <ul><li>The impact of aggressive lipid lowering on clinical events was not evaluated in this trial, particularly given the low-risk of the population. </li></ul><ul><li>The larger JUPITER trial will evaluate the impact of rosuvastatin therapy on clinical events in patients with low to normal levels of LDL but elevated levels of CRP. </li></ul>ACC 2007
  • 10. METEOR Trial: Summary <ul><li>Among asymptomatic patients at low risk for cardiovascular disease, treatment with rosuvastatin was associated with a reduction in CIMT compared with placebo at 2 years. </li></ul>ACC 2007

Related Documents